Hamid Sayar, MD
Associate Professor of Clinical Medicine
Indiana Cancer Pavilion, Suite 473 535 Barnhill Dr
Indianapolis, IN 46202-5289
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Chronic myeloid leukemia within a year of kidney transplant with elevated alkaline phosphatase correlated with imatinib therapy.
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
American Board of Internal Medicine - Internal Medicine
American Board of Internal Medicine - Hematology